Prakash Investment Advisors LLC Purchases Shares of 1,720 Medpace Holdings, Inc. (NASDAQ:MEDP)

Prakash Investment Advisors LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, Holdings Channel reports. The firm purchased 1,720 shares of the company’s stock, valued at approximately $571,000. Medpace accounts for approximately 0.6% of Prakash Investment Advisors LLC’s investment portfolio, making the stock its 26th largest holding.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in Medpace during the fourth quarter valued at about $30,000. Stone House Investment Management LLC purchased a new stake in Medpace during the third quarter valued at about $33,000. Ashton Thomas Securities LLC purchased a new stake in Medpace during the third quarter valued at about $37,000. Capital Performance Advisors LLP purchased a new stake in Medpace during the third quarter valued at about $46,000. Finally, True Wealth Design LLC grew its stake in shares of Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after buying an additional 168 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.3 %

Shares of NASDAQ:MEDP opened at $344.85 on Friday. The stock has a market capitalization of $10.51 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 3.77 and a beta of 1.36. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The stock’s 50-day moving average price is $343.28 and its 200-day moving average price is $347.47.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.